04/15/2026
🔬🌿 A component in cannabis can effectively reverse signs of fatty liver disease.
Scientists have identified that CBD and CBG, two non-psychoactive components of cannabis, can effectively reverse signs of fatty liver disease and metabolic dysfunction.
In a recent study involving obese mice, just four weeks of treatment led to a significant reduction in liver fat and a marked improvement in cholesterol and blood sugar levels. Notably, CBG emerged as a powerful tool for boosting insulin sensitivity and reducing overall body fat, offering a potential breakthrough for a condition that affects one in three adults globally and currently lacks approved pharmacological treatments.
The research highlights a unique biological mechanism: these compounds do not rely on traditional cannabinoid receptors but instead function by increasing levels of phosphocreatine to help cells manage energy more efficiently. While the results provide a promising roadmap for future metabolic therapies, researchers caution that the study is in its early stages. The findings were observed in a laboratory setting using injected doses, meaning further clinical trials are necessary to determine if these benefits will translate to humans using standard oral CBD or CBG products.
What are your thoughts on this potential new avenue for metabolic therapies? Do you think we'll see more research in this area?
For educational purposes. This content is based on publicly available scientific research.